Soluble (s) CD14 and plasmatic lipopolysaccharides (LPS) in patients with chronic hepatitis C before and after treatment with interferon (IFN)-α

Immunopharmacology and Immunotoxicology

Volumn 20, Issue 1, 1998, Pages 1-14

  Jirillo, Emilio ^a,b   Amati, Luigi ^a   Caradonna, Luigi ^a   Greco, Beatrice ^a   Cozzolongo, Raffaele ^a   Cuppone, Renato ^a   Piazzolla, Giuseppina ^b   Caccavo, Domenico ^b   Antonaci, Salvatore ^b   Manghisi, Onofrio G ^a  

^a NATIONAL INSTITUTE FOR DIGESTIVE DISEASES   (Italy)

^b UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BACTERIUM LIPOPOLYSACCHARIDE; BINDING PROTEIN; CD14 ANTIGEN;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; BLOOD LEVEL; CHRONIC HEPATITIS; COMPLEX FORMATION; FEMALE; HEPATITIS C; HUMAN; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PRIORITY JOURNAL;

BACTERIA (MICROORGANISMS); HEPATITIS C VIRUS;

EID: 6844255864     PISSN: 08923973     EISSN: None     Source Type: Journal    
DOI: 10.3109/08923979809034805     Document Type: Article

References (28)

1. Jirillo E., Greco B., Caradonna L. et al. Evaluation of cellular immune responses and soluble mediators in patients with chronic hepatitis C virus (cHCV) infection. Immunopharmacol. Immunotoxicol. 17:347, 1995.
2. Ziegler-Heitbrock HWL, Ulewitch RJ. CD14: cell surface receptor and differentation marker. Immunol. Today 14:121, 1993.
3. Wright S.D., Ramos R. A., Tobias P.S. et al. CD14, receptor for lipopolysaccharide (LPS) and LPS-Binding Protein. Science 249:1431, 1990.
4. Morrison D.C., Danner R.L., Dinarello C.A. et al. Bacterial endotoxins and pathogenesis of gram-negative infections. Current status and future directions. J. Endotoxin Res. 1:71, 1994.
5. Osnes LTN, Westvik AB, Ovstebo R. et al. Lipopolysaccharide activation of human monocytes by CD14 result in a coordinated synthesis of tissue factor, TNF-α and IL-6. J. Endotoxin Res. 2: 27, 1995.
6. Bazil V., Strominger J. Shedding as a mechanism of down-modulation of CD14 on stimulated human monocytes. J. Immunol. 147:1567, 1991.
7. Bufler P., Stieger G., Schuchmann M. et al. Soluble lipopolysaccharide receptor (CD14) is released via two different mechanisms from human monocytes and CD14 transfectants. Eur. J. Immunol. 16:1583, 1986.
8. Grunwald V., Kruger C., Westermann J. et al. An enzyme-linked immunosorbent assay for the quantification of solubized CD14 in biological fluids. J. Immunol. Methods 155:225, 1992.
9. Hallot A., Rong G.W., Silver J. et al. Recombinant soluble CD14 mediates the activation of endothelial cells by lipopolysaccharide. J. Immunol. 151:1500, 1993.
10. Pugin J., Schurer-Maly C.C., Leturq D. et al. Lipopolysaccharide activation of human endothelial and epithelial cells is mediated by lipopolysaccharide-binding protein and soluble CD14. Proc. Natl. Acad. Sci. USA 90:2744, 1993.
11. Zhang J-K., Morrison TK, Falk MC. et al. Characterization of the binding of soluble CD14 to human endothelial cells and mechanisms for CD14-dependent cell activation by LPS. J. Endotoxin Res. 3:307, 1996.
12. Rabinovik R., Neville L.F., Feverstein G. Current understanding of sepsis:criticism and proposal. J. Endotoxin Res. 2:163, 1995.
13. Oesterreicher C., Pfeffel F., Peterman D. et al. Increased in vitro production and serum levels of the soluble lipolysaccharide receptor sCD14 in liver disease. J. Hepatol. 23:396, 1995.
14. Boyum, A., Isolation of mononuclear cells and granulocytes from human blood. Scand. J. Clin. Lab. Invest., 21 (suppl. 97):77, 1968.
15. Antonaci S., Tortorella C., De Simone C. et al. Role of bacterial lipopolysaccharides in the development of natural antibacterial activity mediated by human peripheral blood T lymphocytes. Intern. Rev. Immunol. 6:237, 1990.
16. Cromogenix Laboratory instruction: S-2423. Determination of gram-negative bacterial endotoxins in water and in solutions for parenteral administration.
17. Marchant A., Duchow J., Delville J-P et al. Lipopolysaccharide induces up-regulation of CD14 molecule on monocytes in human whole blood. Eur. J. Immunol. 22:1663, 1992.
18. Landmann R., Wesp M., Ludwig C. et al. Recombinant interferon-γ up-regulates in vivo and down-regulates in vitro monocyte CD14 antigen expression in cancer patients. Cancer Immunol. Immunother. 31:292, 1990.
19. Steinman GG., Rosenkamer F., Leitz G., Clinical experiences with interferon-α and interferon-γ. Int. Rev. Exp. Pathol. 34B:193, 1993.
20. Dianziani F. Interferon toxicity. A mechanistic view trend. Exp. Clin. Med. 4:397, 1995.
21. Jirillo E., Greco B., Caradonna L. et al. Immunological effects following administration of interferon-α in patients with chronic hepatitis C virus (cHCV) infection. Immunopharmacol. Immunotoxicol. 18:335, 1996.
22. Jack RS., Grunwald V., Stelter F. et al. Both membrane-bound and soluble forms of CD14 bind to gram-negative bacteria. Eur. J. Immunol. 25:604, 1995.
23. Hailman E., Vasselon T., Kelley M. et al. Stimulation of macrophages and neutrophils by complexes of lipopolysaccharide and soluble CD14. J. Immunol. 156:4384, 1996.
24. Giannelli G., Piazzolla G., Tortorella C. et al. Neutrophil oxidative responsiveness in chronic hepatitis C. Med. Sci. Res. 24:99, 1996.
25. Piazzolla G., Giannelli G., Antonelli G. et al. Effects of interferon-α treatment on neutrophil oxidative metabolism, lymphocyte proliferation and monocyte HLA class antigen expression in patients with chronic hepatitis C. Immunopharmacol. Immunotoxicol. 18:529, 1996.
26. Nockker WA., Wigand R., Schoeppe W. et al. Elevated levels of soluble CD14 in serum of patients with Systemic Lupus Erythematosus. Clin. Exp. Immunol. 96:15, 1994.
27. Nockker WA., Bergmann L., Scherberich J.E. Increased soluble CD14 serum levels and altered CD14 expression of peripheral blood monocytes in HCV-infected patients. Clin. Exp. Immunol. 98:369, 1994.
28. Kruger C., Shutt C., Obertacke V. Serum CD14 levels in polytraumatized and severely burned patients. Clin. Exp. Immunol. 85:297, 1991.